Shanghai Shen Lian Biomedical (SHSE:688098) DeferredTaxAndRevenue: ¥0.0 Mil (As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Shanghai Shen Lian Biomedical Corp SHSE:688098

70 GF Score

Price ¥8.41

GF Value ¥5.85

Valuation Significantly Overvalued

2 Warning Signs

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

What is Shanghai Shen Lian Biomedical DeferredTaxAndRevenue?

Shanghai Shen Lian Biomedical SHSE:688098 +0.48% 70 DeferredTaxAndRevenue is ¥0.0 Mil as of Mar. 2026. GuruFocus rates SHSE:688098 with a GF Score™ of 70/100 and a GF Value™ of ¥5.85 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Shanghai Shen Lian Biomedical's current deferred tax and revenue for the quarter that ended in Mar. 2026 was ¥0.0 Mil.

Try GuruFocus Premium free for 7 days

Unlock GF Score, GF Value, 30-Y financials, and pro screeners.

Get Started →

Shanghai Shen Lian Biomedical DeferredTaxAndRevenue Related Terms

Shanghai Shen Lian Biomedical DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Shanghai Shen Lian Biomedical's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Shen Lian Biomedical DeferredTaxAndRevenue Chart

Shanghai Shen Lian Biomedical Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

DeferredTaxAndRevenue

Get a 7-Day Free Trial

0.00

Shanghai Shen Lian Biomedical Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
DeferredTaxAndRevenue	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

70GF Score

Shanghai Shen Lian Biomedical Corp SHSE:688098

DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

Frequently Asked Questions Learn more about DeferredTaxAndRevenue →

What does a DeferredTaxAndRevenue of ¥0.0 Mil mean?

Shanghai Shen Lian Biomedical (SHSE:688098) has a DeferredTaxAndRevenue of ¥0.0 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Shanghai Shen Lian Biomedical.

Is Shanghai Shen Lian Biomedical's DeferredTaxAndRevenue too high?

Shanghai Shen Lian Biomedical's current DeferredTaxAndRevenue is ¥0.0 Mil. Overall, Shanghai Shen Lian Biomedical has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Shanghai Shen Lian Biomedical's DeferredTaxAndRevenue compare to VRTX and REGN?

Shanghai Shen Lian Biomedical's DeferredTaxAndRevenue of ¥0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good DeferredTaxAndRevenue for a Biotechnology company?

A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high DeferredTaxAndRevenue mean?

A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Shanghai Shen Lian Biomedical. Shanghai Shen Lian Biomedical's current DeferredTaxAndRevenue is ¥0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Shanghai Shen Lian Biomedical stock overvalued right now?

Based on GuruFocus' analysis, Shanghai Shen Lian Biomedical (SHSE:688098) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥5.85, compared to a current price of ¥8.41 — trading 43.8% above its estimated fair value. The current DeferredTaxAndRevenue is ¥0.0 Mil. Shanghai Shen Lian Biomedical's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is DeferredTaxAndRevenue calculated?

DeferredTaxAndRevenue is calculated from a company's financial statements. For Shanghai Shen Lian Biomedical (SHSE:688098), the current DeferredTaxAndRevenue is ¥0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Shen Lian Biomedical (SHSE:688098) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Shen Lian Biomedical stock appears to be overvalued. The current stock price of ¥8.41 is trading 43.8% above its estimated GF Value™ of ¥5.85. GuruFocus considers Shanghai Shen Lian Biomedical to be Significantly Overvalued.

Key valuation signals for SHSE:688098:

DeferredTaxAndRevenue: ¥0.0 Mil
GF Value™: ¥5.85 vs. price of ¥8.41 (43.8% above fair value)
GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688098 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →